<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003564</url>
  </required_header>
  <id_info>
    <org_study_id>DM97-050</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-97050</secondary_id>
    <secondary_id>NCI-T97-0078</secondary_id>
    <secondary_id>CDR0000066630</secondary_id>
    <nct_id>NCT00003564</nct_id>
  </id_info>
  <brief_title>Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas</brief_title>
  <official_title>Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known whether giving procarbazine alone or with isotretinoin is more effective for&#xD;
      recurrent primary malignant glioma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of procarbazine alone or&#xD;
      with isotretinoin in treating patients with recurrent primary malignant gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether the combination of isotretinoin and procarbazine can improve&#xD;
      time to progression and survival compared to procarbazine alone in patients with recurrent&#xD;
      malignant gliomas. II. Document the toxicity of these two regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive&#xD;
      procarbazine alone or in combination with isotretinoin. Arm I: Patients receive oral&#xD;
      procarbazine once daily on days 1-14 every 28 days. Oral isotretinoin is administered every&#xD;
      12 hours on days 15-28 every 28 days. Patient receive 6 courses of combined therapy, then&#xD;
      continue with oral isotretinoin alone on days 15-28 of each 28 day course, until disease&#xD;
      progression or unacceptable toxicity. Arm II: Patients receive procarbazine by mouth once&#xD;
      daily on days 1-14 followed by 2 weeks of rest. Patients receive a total of 6 courses of&#xD;
      treatment in the absence of disease progression and unacceptable toxicity. Patients are&#xD;
      followed until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue a total of 194 patients (97 per treatment group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn.&#xD;
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression for Procarbazine alone or with Isotretinoin</measure>
    <time_frame>Six 28-day cycles</time_frame>
    <description>Effectiveness of procarbazine alone or with isotretinoin in treating patients with recurrent primary malignant gliomas measuring time to disease progression (in days).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Arm I (Procarbazine + Isotretinoin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Procarbazine Alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.</description>
    <arm_group_label>Arm I (Procarbazine + Isotretinoin)</arm_group_label>
    <other_name>Accutane</other_name>
    <other_name>13-cis-retinoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine Hydrochloride</intervention_name>
    <description>Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.&#xD;
Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.</description>
    <arm_group_label>Arm I (Procarbazine + Isotretinoin)</arm_group_label>
    <arm_group_label>Arm II (Procarbazine Alone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven primary malignant gliomas including the&#xD;
        following: Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic&#xD;
        oligodendroglioma Anaplastic infiltrating glioma Mixed malignant gliomas Must show evidence&#xD;
        of tumor recurrence or progression on at least 2 serial enhanced MRI scans Must have&#xD;
        measurably enhancing residual disease on MRI or CT scan of brain&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 60-100% Life&#xD;
        expectancy: Greater than 8 weeks Hematopoietic: Absolute granulocyte count at least&#xD;
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: SGPT less than 2 times institutional&#xD;
        normal Alkaline phosphatase less than 2 times institutional normal Bilirubin less than 1.5&#xD;
        mg/dL Renal: BUN less than 1.5 times institutional normal OR Creatinine less than 1.5 times&#xD;
        institutional normal Other: No active infection Not pregnant or nursing Fertile patients&#xD;
        must use effective contraception 1 month before, during, and 1 month after study No other&#xD;
        disease that will obscure toxicity or alter drug metabolism No other concurrent medical&#xD;
        illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        procarbazine No prior isotretinoin At least 4 weeks since prior chemotherapy (6 weeks for&#xD;
        nitrosoureas) and recovered Endocrine therapy: Not specified Radiotherapy: Prior&#xD;
        radiotherapy allowed Surgery: Not specified Other: No concurrent tetracyclines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt A. Jaeckle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>February 17, 2012</last_update_submitted>
  <last_update_submitted_qc>February 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

